Last updated on June 2019

Firazyr Patient Registry (Icatibant Outcome Survey - IOS)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: HEREDITARY ANGIOEDEMA
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Diagnosis of at least 1 of the following:
    • Hereditary angioedema (HAE) type I or II
    • HAE with normal C1 inhibitor
    • ACE-I-induced angioedema
    • Non-histaminergic idiopathic angioedema
    • Acquired angioedema.
  2. Signed and dated written informed consent from the participant or, for participants aged less than(<)18 years (or as per local regulation, such as <16 years in the United Kingdom [UK]), parent and/or participants legally authorized representative (LAR), and assent of the minor where applicable.
  3. At sites only participating in the drug registry, participants must have taken at least 1 dose of Firazyr (Icatibant) or Cinryze (C1 inhibitor [human]).
  4. Enrolled participants in Germany taking Firazyr (Icatibant) or Cinryze (C1 inhibitor [human]) will only use the respective product in accordance with the product label.

Exclusion Criteria:

  1. Participants enrolled in clinical trials where the product is blinded or where the product under investigation is for the treatment of HAE, ACE-I-induced angioedema, non-histaminergic idiopathic angioedema, or acquired angioedema.
  2. Participants enrolled in another Shire-sponsored registry involving products for the treatment of HAE, ACE-I-induced angioedema, non-histaminergic idiopathic angioedema, or acquired angioedema. An exception applies to participants enrolled in the Shire lanadelumab ENABLE study.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.